Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

February 7th 2023

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

Targetable Mutations Found in Breast Cancers

February 7th 2023

Shared insight on key driver mutations and corresponding precision medicine in the setting of breast cancer management.

Use of Second-Generation Oral SERDs in ER+/HER2- mBC

February 7th 2023

Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.

Treatment after Progression on CDK4/6 Inhibitors

February 6th 2023

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

The Role of Surgery in Breast Cancer

February 6th 2023

Experts in oncology consider when surgery is appropriate for patients with breast cancer.

WHO Outlines New Framework for Early Detection and Management of Breast Cancer

February 3rd 2023

The World Health Organization has released new framework guidelines with the goal of saving 2.5 million lives from breast cancer by 2040 through a combination of early detection, timely diagnosis, and comprehensive management.

Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast Cancer

February 3rd 2023

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

Dr. Boughey on Key Results From the ACOSOG Z11102 Trial in Multiple Ipsilateral Breast Cancer

February 3rd 2023

Judy C. Boughey, MD, discusses the significance of results from the phase 2 ACOSOG Z11102 trial evaluating breast conserving therapy in multiple ipsilateral breast cancer.

FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer

February 3rd 2023

The FDA has approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.

Dr. Lang on the Potential Applications for the Parsortix® PC1 System in Breast Cancer

February 2nd 2023

Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

NCCN Adds Neratinib to New Metastatic Breast Cancer Guidelines

February 1st 2023

In recommendations released January 27, 2023, the National Comprehensive Cancer Network now advises physicians to consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of estrogen receptor status, with activating mutations in the HER2 gene as detected by next-generation sequencing of tumor tissue or circulating tumor DNA.

Dr. Costa on the Efficacy of Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage TNBC

February 1st 2023

Ricardo Costa, MD, MSC, discusses the use of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab monotherapy, in patients with high-risk, early-stage triple-negative breast cancer.

The Emerging State of HER2-low Breast Cancer

February 1st 2023

Dr Geyer and Dr Krop discuss key data and the evolving standard of care for patients with HER2-low breast cancer.

Unmet Needs for Patients with HER2+ Breast Cancer with Brain Metastases

February 1st 2023

Breast cancer experts exchange thoughts on the treatment of HER2+ breast cancer with CNS involvement, particularly the use of trastuzumab deruxtecan in this subset of patients.

Dr. Gupta on the Use of Platinum Plus Standard Neoadjuvant Chemotherapy in TNBC

January 31st 2023

Sudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer.

Dr. Chavez Mac Gregor on Key Results From SWOG S1207 in HR+/HER2- Breast Cancer

January 31st 2023

Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.

Standards of Care in the Frontline Treatment of ER+/HER2- mBC

January 30th 2023

Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.

Overview of ER+/HER2- Metastatic Breast Cancer (mBC)

January 30th 2023

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.